Arcus Biosciences (NYSE: RCUS) recently received a number of ratings updates from brokerages and research firms: 11/5/2026 – Arcus Biosciences had its price target raised by Leerink Partners from $46.00 to $49.00. They now have an “outperform” rating on the stock. 11/5/2026 – Arcus Biosciences had its price target lowered by Truist Financial from $41.00 […]

A number of research firms have changed their ratings and price targets for ARM (NASDAQ: ARM): 11/5/2026 – ARM had its price target lowered by TD Cowen from $350.00 to $250.00. They now have a “buy” rating on the stock. 11/5/2026 – ARM had its price target lowered by Royal Bank Of Canada from $340.00 […]

Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates: 11/6/2026 – Rhythm Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $145.00 to $142.00. They now have an “overweight” rating on the stock. 11/5/2026 – Rhythm Pharmaceuticals had its price target raised by Guggenheim from […]

A number of firms have modified their ratings and price targets on shares of Precigen (NASDAQ: PGEN) recently: 11/8/2026 – Precigen was upgraded by Wall Street Zen from “buy” to “strong-buy”. 11/5/2026 – Precigen was given a new $12.00 price target by Raymond James Financial. 11/5/2026 – Precigen had its “market outperform” rating reaffirmed by […]

Celcuity (NASDAQ: CELC) has recently received a number of price target changes and ratings updates: 11/9/2026 – Celcuity had its “market outperform” rating reaffirmed by Citigroup. 11/9/2026 – Celcuity had its price target lowered by HC Wainwright from $155.00 to $150.00. They now have a “buy” rating on the stock. 11/6/2026 – Celcuity is now […]

Manhattan Associates (NASDAQ: MANH) recently received a number of ratings updates from brokerages and research firms: 11/2/2026 – Manhattan Associates had its price target raised by Barclays from $239.00 to $275.00. They now have an “overweight” rating on the stock. 11/1/2026 – Manhattan Associates was downgraded by Wall Street Zen from “buy” to “hold”. 10/28/2026 […]

Several analysts have recently updated their ratings and price targets for Sprouts Farmers Market (NASDAQ: SFM): 11/5/2026 – Sprouts Farmers Market was downgraded by Northcoast Research from “buy” to “neutral”. 11/2/2026 – Sprouts Farmers Market had its price target lowered by Jefferies Financial Group from $95.00 to $63.00. They now have a “buy” rating on […]

Several brokerages have updated their recommendations and price targets on shares of Citizens (NASDAQ: CIZN) in the last few weeks: 11/9/2026 – Citizens was given a new $5.50 price target by Wells Fargo & Company. 11/9/2026 – Citizens had its “market outperform” rating reaffirmed by Citigroup. 11/4/2026 – Citizens had its “market perform” rating reaffirmed […]

A number of firms have modified their ratings and price targets on shares of GE HealthCare Technologies (NASDAQ: GEHC) recently: 11/3/2026 – GE HealthCare Technologies had its price target raised by UBS Group from $73.00 to $80.00. They now have a “neutral” rating on the stock. 10/31/2026 – GE HealthCare Technologies was upgraded by Wall […]

Several brokerages have updated their recommendations and price targets on shares of Harmony Biosciences (NASDAQ: HRMY) in the last few weeks: 11/8/2026 – Harmony Biosciences was downgraded by Wall Street Zen from “buy” to “hold”. 10/31/2026 – Harmony Biosciences was downgraded by Wall Street Zen from “strong-buy” to “buy”. 10/29/2026 – Harmony Biosciences was given […]

RTB Digital, Inc. Common Stock (NASDAQ:RTB – Get Free Report) and Atlassian (NASDAQ:TEAM – Get Free Report) are both technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation. Earnings and Valuation This table compares […]

Manhattan Associates (NASDAQ:MANH – Get Free Report) and RTB Digital, Inc. Common Stock (NASDAQ:RTB – Get Free Report) are both technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends. Analyst Ratings This is a […]